CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients. After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA—were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine by researchers from the Abramson Cance
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA—were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.
- Ponto de atenção: cell.
- Ponto de atenção: therapy.
- Ponto de atenção: leads.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
